Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

All NewsJune 12, 2026

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh divesiran’s profile against rusfertide.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

The UCW Newswire : Financial, Business and Tech News

Recent Headlines

Republicans paid the price for Trump’s failed policies

Amazon’s $11 multi-functional desk organizer has drawers and trays

Amazon is selling a $40 heavy-duty shelf with 4 tiers that can hold up to 1,000 pounds

Morning in America, twilight in the markets

The next US presidential race has begun